27 results on '"Siudut J"'
Search Results
2. P-selectin as a modulator of fibrin clot properties in patients treated with high-dose statins
- Author
-
Siudut, J., primary, Zabczyk, M., additional, Polak, M., additional, Jawień, J., additional, and Undas, A., additional
- Published
- 2022
- Full Text
- View/download PDF
3. Neutrophil extracellular traps formation in patients with eosinophilic granulomatosis with polyangiitis : association with eosinophilic inflammation
- Author
-
Natorska, J., Michał Ząbczyk, Siudut, J., Krawiec, P., Mastalerz, L., and Undas, A.
- Published
- 2017
4. Reduced Plasma Fibrin Clot Permeability and Susceptibility to Lysis Are Associated With Increased Risk of Post-Thrombotic Syndrome
- Author
-
Siudut, J., primary, Grela, M., additional, and Wypasek, E., additional
- Published
- 2016
- Full Text
- View/download PDF
5. VISCOELASTIC PROPERTIES OF PLASMA FIBRIN CLOTS ARE SIMILAR IN PATIENTS ON RIVAROXABAN AND VITAMIN K ANTAGONISTS.
- Author
-
KOPYTEK, M., ZABCZYK, M., NATORSKA, J., SIUDUT, J., MALINOWSKI, K. P., PTASZEK, P., GLAJCAR, A., GORALCZYK, T., and UNDAS, A.
- Subjects
FIBRIN ,THROMBOEMBOLISM ,VISCOELASTICITY ,RIVAROXABAN ,VITAMIN K ,ANTICOAGULANTS - Abstract
Unfavorable fibrin clot features have been observed in patients with venous thromboembolism (VTE). We investigated whether rivaroxaban, a direct factor Xa inhibitor, and vitamin K antagonists (VKAs) can improve plasma clot viscoelastic properties. We studied four age- and sex-matched groups: 25 healthy controls, 15 VTE patients taking rivaroxaban 20 mg/day (blood concentration, 145 (67 - 217) ng/ml), 15 VTE patients taking VKA (INR: 2 - 3), and 15 VTE patients who stopped oral anticoagulant therapy (OAT). Using a hybrid rheometer the storage (G') and loss (G") moduli were evaluated in citrated plasma after addition of 5 pmol/l tissue factor. Fiber thickness within clots was assessed using scanning electron microscopy. Higher G' but not G" was observed for VTE patients taking rivaroxaban (+34%; post hoc, P = 0.029) compared to controls. As reflected by lower G' and G", patients taking rivaroxaban (-19% and -30%;post hoc, P = 0.0013 and P < 0.0001, respectively) formed less stiff and viscous clots compared to VTE patients after OAT withdrawal, also after adjustment for fibrinogen. VTE patients treated with rivaroxaban and VKA had similar clot viscoelastic properties (post hoc, P = 0.85 for G' and P = 0.29 for G"). G' and G" correlated with plasma rivaroxaban concentrations (r = -0.67, P = 0.005 and r = -0.59, P = 0.021, respectively), and the time from the last dose of rivaroxaban intake (r = 0.59, P = 0.02 and r = 0.58, P = 0.022, respectively). G' and G" showed no association with INR in patients on VKAs. G' or G" were not associated with fibrin diameter on scanning electron microscopy images in either group. Our preliminary study shows that both rivaroxaban and VKA improve clot viscoelastic properties in VTE patients, which might contribute to their antithrombotic effects. G' and G" may reflect specific clot physical features, beyond key plasma clot characteristics, which highlights benefits from comprehensive plasma clot analysis in patients with thrombotic diseases. [ABSTRACT FROM AUTHOR]
- Published
- 2019
- Full Text
- View/download PDF
6. Corrosion rate measurement for steel sheets of a fuel tank shell being in service
- Author
-
Maslak Mariusz and Siudut Janusz
- Subjects
fuel tank ,steel tank shell ,corrosion rate ,durability prediction ,in situ measurements ,trend of corrosion progress ,Engineering (General). Civil engineering (General) ,TA1-2040 - Abstract
Some corrosion progress trends specific for cylindrical steel shells of typical above-ground fuel tanks are first identified experimentally and then quantitatively compared with one another. The inference is based on many random thickness measurements related to the selected corrosively weakened coating sheets and carried out at various moments of the tanks in question service time. It is shown in detail that in this type of structures, due to the manner of their use and, particularly, the material stored inside, the corrosion process is in general significantly accelerated over time. For this reason, a nonlinear formal model describing the simulated corrosion development anticipated for the future fuel tank service time seems to be the best choice in forecasting its remaining time to failure.
- Published
- 2021
- Full Text
- View/download PDF
7. Elevated plasma factor XI is associated with postthrombotic syndrome.
- Author
-
Stępień K, Siudut J, Zalewski J, Nowakowski T, and Undas A
- Subjects
- Humans, Female, Male, Adult, Middle Aged, Venous Thrombosis blood, Postthrombotic Syndrome blood, Factor XI metabolism
- Abstract
Introduction: Postthrombotic syndrome (PTS), a common complication of deep vein thrombosis (DVT), is largely inflammatory by nature with contribution of prothrombotic mechanisms. The role of factor (F)XI in PTS has not been explored yet. We investigated whether elevated FXI is associated with PTS occurrence., Materials and Methods: We enrolled 180 consecutive patients (aged 43 ± 13 years) with first-ever DVT. After 3 months FXI levels were measured, along with inflammatory markers, thrombin generation, plasma clot permeability (Ks), clot lysis time (CLT), and fibrinolysis proteins. We assessed PTS using the Villalta score and recorded symptomatic venous thromboembolism (VTE) at a 1-year and venous ulcers at a median 53 months follow-up., Results: Baseline median FXI was 102 % [IQR 92-113 %] and showed positive association with Villalta score (R = 0.474, P < 0.001). Patients with PTS (n = 48, 26.7 %) had 16.1 % higher FXI (P < 0.001) and FXI ≥120 % occurred more often in PTS patients (odds ratio [OR] 5.55, 95 % confidence interval [CI] 2.28-13.47). There were associations of baseline FXI with Ks and CLT along with thrombin activatable fibrinolysis inhibitor (TAFI) activity, C-reactive protein, and interleukin-6, but not with fibrinogen, or thrombin generation. After age adjustment higher FXI was independently associated with PTS occurrence (OR per 1 % 1.06, 95 % CI 1.02-1.09) and VTE recurrence (OR 1.03, 95 % CI 1.01-1.06). At long-term follow-up, patients with venous ulcers had 13.6 % higher baseline FXI (P = 0.002)., Conclusions: Elevated FXI in association with inflammation and prothrombotic fibrin clot properties may contribute to the development of PTS following DVT., Competing Interests: Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper., (Copyright © 2024 Elsevier Ltd. All rights reserved.)
- Published
- 2024
- Full Text
- View/download PDF
8. Effect of high-dose statin therapy on coagulation factors: Lowering of factor XI as a modifier of fibrin clot properties in coronary artery disease.
- Author
-
Stępień K, Siudut J, Konieczyńska M, Nowak K, Zalewski J, and Undas A
- Subjects
- Humans, Fibrin, Factor XI, Fibrinolytic Agents, Cholesterol, LDL, Rosuvastatin Calcium adverse effects, Thrombin, Blood Coagulation Factors, Hydroxymethylglutaryl-CoA Reductase Inhibitors adverse effects, Coronary Artery Disease diagnosis, Coronary Artery Disease drug therapy, Thrombosis diagnosis, Thrombosis drug therapy, Thrombosis prevention & control
- Abstract
Background: Multiple pleiotropic effects of statins include antithrombotic properties with formation of looser fibrin networks more susceptible to lysis. Recently, rosuvastatin 20 mg/d has been reported to decrease coagulation factors (F) VII, FVIII and FXI in venous thrombosis patients., Objectives: We investigated how high-dose statin therapy recommended in coronary artery disease (CAD) alters plasma levels of coagulation factors and if such changes might affect fibrin clot properties., Methods: We studied 130 advanced CAD patients, who initially did not achieve the target low-density lipoprotein cholesterol (LDL-C). Before high-dose statin therapy (rosuvastatin 40 mg/d or atorvastatin 80 mg/d) and 6-12 months after its initiation, FII, FV, FVII, FVIII, FIX, FX, FXI and fibrinogen were assessed. We evaluated the impact of statin-induced alterations to the factors on plasma fibrin clot permeability (Ks) reflecting a fibrin pore size, and clot lysis time (CLT) reflecting fibrinolytic potential., Results: At baseline LDL-C (median 3.2, interquartile range 2.7-3.7 mmol/L) was independently associated solely with FXI (β = 0.58, P < 0.001). Median LDL-C reduction by 25% (P < 0.001) on high-dose statin treatment was accompanied by lowering of FVII, FVIII, and FXI (for all P < 0.001). On high-dose statin treatment, Ks (R = 0.65, P < 0.001) inversely associated with CRP (β = -0.41, P < 0.001), LDL-C (β = -0.26, P = 0.001), and FXI (β = -0.18, P = 0.016). In turn, CLT (R = 0.45, P < 0.001) was positively associated with LDL-C (β = 0.19, P = 0.043) and FXI (β = 0.17, P = 0.049)., Conclusions: High-dose statin therapy in CAD patients decreases FVII, FVIII, and FXI. The statin-induced reduction in FXI may contribute to less prothrombotic fibrin clot phenotype, indicating additional antithrombotic effect of high-dose statins., Competing Interests: Declaration of Competing Interest The authors of this manuscript have nothing to declare., (Copyright © 2023 Elsevier Inc. All rights reserved.)
- Published
- 2023
- Full Text
- View/download PDF
9. Therapy with high-dose statins reduces soluble P-selectin: The impact on plasma fibrin clot properties.
- Author
-
Siudut J, Pudło J, Konieczyńska M, Polak M, Jawień J, and Undas A
- Subjects
- Humans, Fibrin metabolism, Thrombin metabolism, P-Selectin pharmacology, Fibrinolysis, Hydroxymethylglutaryl-CoA Reductase Inhibitors pharmacology, Thrombosis diagnosis, Thrombosis drug therapy
- Abstract
Objective: Studies on the effect of statins on platelets in patients with coronary artery disease (CAD) yielded inconsistent results. We sought to investigate whether high-dose statin therapy reduces plasma concentrations of soluble P-selectin (sP-selectin), a well-established platelet activation marker and if such changes can affect fibrin clot properties, which are unfavorably altered in CAD patients., Methods: We studied 130 consecutive patients with advanced CAD who did not achieve the target LDL cholesterol on statins. At baseline and after 6-12 months of treatment with atorvastatin 80 mg/day or rosuvastatin 40 mg/day, soluble plasma sP-selectin, along with plasma fibrin clot permeability (Ks), clot lysis time (CLT), thrombin generation and fibrinolysis proteins were determined., Results: Before high-intensity statin treatment, lower Ks and longer CLT values were associated with increased sP-selectin (β -0.27 [95% CI -0.44 to -0.10] and β 0.21 [95% CI 0.01 to 0.41]; both p < 0.05, respectively) also after adjustment for potential confounders. sP-selectin, alongside fibrin features and other variables at baseline showed no association with lipid profile. On high-dose statin therapy, there was 32% reduction in sP-selectin levels (p < 0.001). On-treatment change (Δ) in sP-selectin correlated with ΔKs and ΔCLT (r = -0.32, p < 0.001 and r = 0.22, p = 0.011, respectively), but not with cholesterol and C-reactive protein lowering. We did not observe any associations between post-treatment sP-selectin levels and lipids, fibrin clot properties or thrombin generation., Conclusions: High-dose statin therapy reduces markedly sP-selectin levels in association with improved fibrin clot phenotype, which highlights the contribution of platelet-derived proteins to a prothrombotic state in hypercholesterolemia and statin-induced antithrombotic effects., Competing Interests: Declaration of Competing Interest The authors of this manuscript have nothing to declare., (Copyright © 2022 Elsevier B.V. All rights reserved.)
- Published
- 2023
- Full Text
- View/download PDF
10. Oxidized phospholipids associated with lipoprotein(a) contribute to hypofibrinolysis in severe aortic stenosis.
- Author
-
Kopytek M, Ząbczyk M, Mazur P, Siudut J, and Natorska J
- Subjects
- Humans, Phospholipids, Oxidation-Reduction, Lipoprotein(a), Aortic Valve Stenosis complications
- Published
- 2022
- Full Text
- View/download PDF
11. Unfavorably altered fibrin clot properties are associated with recurrent venous thromboembolism in patients following post‑discharge events.
- Author
-
Undas KW, Siudut J, and Ząbczyk M
- Subjects
- Aftercare, Fibrin, Fibrin Clot Lysis Time, Humans, Patient Discharge, Thrombosis, Venous Thromboembolism etiology
- Published
- 2022
- Full Text
- View/download PDF
12. Intensive low-density lipoprotein cholesterol lowering improves fibrin clot properties: Association with lipoproteins and C-reactive protein.
- Author
-
Siudut J, Ząbczyk M, Wołkow P, Polak M, Undas A, and Jawień J
- Subjects
- C-Reactive Protein, Cholesterol, LDL, Fibrin metabolism, Fibrinolysis, Humans, Thrombin metabolism, Hydroxymethylglutaryl-CoA Reductase Inhibitors pharmacology, Hydroxymethylglutaryl-CoA Reductase Inhibitors therapeutic use, Thrombosis drug therapy, Thrombosis prevention & control
- Abstract
Objective: Dense fibrin networks resistant to lysis characterize coronary artery disease (CAD) patients. We investigated whether a statin-induced decrease of low-density lipoprotein cholesterol (LDL-C) could improve fibrin clot phenotype in CAD patients., Methods: We recruited 130 consecutive patients with advanced CAD (baseline LDL-C of 4.4 [IQR, 3.8-4.8] mmol/L), who on statins did not achieve the LDL-C goal based on the 2016 ESC/EAS guidelines. On standard statin treatment and after 6-12 months of high-dose statin treatment (atorvastatin 80 mg/day or rosuvastatin 40 mg/day), plasma fibrin clot permeability (Ks), clot lysis time (CLT), thrombin generation, coagulation and fibrinolytic factors were determined., Results: After a median high-dose statin therapy of 7 months there was 25% reduction in LDL-C associated with increased Ks and shorter CLT, together with lower thrombin activatable fibrinolysis inhibitor, factor VIII, D-dimer, and C-reactive protein (CRP); thrombin generation was unaltered. The patients who achieved the therapeutic goal (n = 49, 37.7%) had 29.2% increase in Ks and 16.3% shorter CLT compared with the standard therapy, while there were no similar changes in the remaining patients. After adjustment for potential confounders, including CRP, an increase in Ks (by 1 × 10
-9 cm2 ) and decrease in CLT (by 10 min) were independently predicted by on-treatment LDL-C goal (odds ratio [OR] 6.23, 95% confidence interval [CI] 1.97-20.33 and OR 3.11, 95% CI 1.05-8.99, respectively)., Conclusions: For the first time we showed that a decrease of LDL-C ≤ 1.8 mmol/L, or a reduction of at least 50% if the baseline LDL-C is between 1.8 and 3.5 mmol/L, is associated with favorable alterations to fibrin clot phenotype, with a stronger impact of lipoprotein reduction than CRP lowering, which might suggest that other potent cholesterol-lowering drugs can exert similar antithrombotic actions., (Copyright © 2022 Elsevier Inc. All rights reserved.)- Published
- 2022
- Full Text
- View/download PDF
13. Apolipoproteins and lipoprotein(a) as factors modulating fibrin clot properties in patients with severe aortic stenosis.
- Author
-
Siudut J, Natorska J, Wypasek E, Wiewiórka Ł, Ostrowska-Kaim E, Wiśniowska-Śmiałek S, Plens K, Musialek P, Legutko J, and Undas A
- Subjects
- Apolipoproteins, Apolipoproteins B, Fibrin Clot Lysis Time, Fibrinolysis, Humans, Lipoprotein(a), Proteomics, Aortic Valve Stenosis, Fibrin analysis
- Abstract
Background and Aims: Large amounts of clot-bound lipoproteins were reported in proteomic analysis of plasma clot but their impact on fibrin clot properties is unknown. We investigated a contribution of lipid profile and apolipoproteins (apo) to the prothrombotic plasma fibrin clot phenotype in patients with aortic stenosis (AS)., Methods: In 138 patients with isolated severe AS, we determined serum apoA-I, A-II, B, C-II, C-III, E, oxidized low-density lipoprotein (OxLDL) and lipoprotein(a) concentrations. Plasma fibrin clot permeability (Ks), maximal absorbance (MaxAbs
CLT2018 and MaxAbsLys50 ), and fibrinolytic capacity were studied using 3 plasma-based lysis assays (CLT2018, CLT, and Lys50), and compared with well-matched patients without AS (control group)., Results: After adjustment for confounding factors, including statin use, only low-density lipoprotein cholesterol (LDL-C) and apoB levels were inversely associated with Ks. Triglycerides, apoC-II, and C-III were associated with MaxAbsCLT2018 and MaxAbsLys50 , explaining 56-64% of their variability. CLT2018 and CLT showed associations with total cholesterol, LDL-C, triglycerides, and OxLDL as well as with apoB, C-II, C-III, and E. ApoA-I, C-II, and C-III but not serum lipids were associated with Lys50. Only CLT2018 was associated with lipoprotein(a). ApoC-III, B, A-I, and E along with estimated glomerular filtration rate and OxLDL predicted hypofibrinolysis in multiple regression analysis. AS patients had higher lipoprotein(a) (+34.9%) and apoA-I (+25.9%) levels and less compact fibrin clots (-13.3% lower MaxAbsCLT2018 , -53.2% lower MaxAbsLys50 , and +28.3% higher Ks) displaying higher susceptibility to lysis (-17.9% lower Lys50) in comparison with control group., Conclusions: Apolipoproteins and OxLDL contribute to prothrombotic fibrin clot phenotype in severe AS. Moreover, apolipoproteins better than serum lipids predicted hypofibrinolysis, which provides additional argument for a role of elevated lipoproteins in the prothrombotic state., (Copyright © 2022 Elsevier B.V. All rights reserved.)- Published
- 2022
- Full Text
- View/download PDF
14. Determinants of plasma fibrin clot lysis measured using three different assays in healthy subjects.
- Author
-
Siudut J, Iwaniec T, Plens K, Pieters M, and Undas A
- Subjects
- Female, Fibrin Clot Lysis Time, Fibrinolysis, Healthy Volunteers, Humans, Carboxypeptidase B2, Fibrin
- Abstract
Introduction: Several methods for measuring fibrinolytic capacity in plasma have been developed yielding frequently inconsistent results. We investigated which factors determine fibrinolytic capacity in three plasma-based assays., Material and Methods: In 80 apparently healthy controls (aged 43 ± 10 years, 50 women [62.5%]) we evaluated fibrinolysis using three assays: (1) by Pieters et al. (CLT2018), (2) by Lisman et al. (CLT), and (3) by Carter et al. (Lys50). Coagulation factors and fibrinolytic proteins, including histidine-rich glycoprotein (HRG) and γ'-fibrinogen, were determined. Regression models were performed to identify determinants of lysis times., Results: Positive correlations were observed between CLT2018 and both CLT (r = 0.73) and Lys50 (r = 0.61), as well as between CLT and Lys50 (r = 0.46, all p < 0.001). The main determinants of both CLT2018 and CLT were plasminogen activator inhibitor-1 (PAI-1), followed by thrombin-activatable fibrinolysis inhibitor (TAFI) and α
2 -antiplasmin. Histidine-rich glycoprotein was a predictor of the longest-normal CLT2018 alone (OR 1.04, 95% CI 1.02-1.06). α2 -Antiplasmin and fibrinogen levels, followed by PAI-1 and TAFI determined Lys50. After adjustment for age, sex, and body mass index, C-reactive protein (CRP) was an independent predictor of the top quartiles of the three lysis times., Conclusions: We showed that apart from PAI-1, TAFI, and α2 -antiplasmin, several other factors, in particular CRP, can affect the results of global fibrinolysis tests used in research. Our findings may help understand why the choice of a specific fibrinolysis assay can affect the presence and/or magnitude of intergroup differences in fibrinolytic capacity in a given disease state., (Copyright © 2020 Elsevier Ltd. All rights reserved.)- Published
- 2021
- Full Text
- View/download PDF
15. Patients scheduled for TAVI tend to form abnormal fibrin clots more resistant to lysis: the impact of age.
- Author
-
Jaworska-Wilczyńska M, Natorska J, Siudut J, Marzec K, Kowalik I, Hryniewiecki T, and Undas A
- Subjects
- Aortic Valve, Blood Coagulation, Fibrin, Fibrin Clot Lysis Time, Fibrinolysis, Humans, Risk Factors, Aortic Valve Stenosis surgery, Heart Valve Prosthesis Implantation, Transcatheter Aortic Valve Replacement adverse effects
- Abstract
Background: Fibrin accumulation within the stenotic leaflets associated with impaired fibrinolysis was observed in severe aortic stenosis (AS). Little is known about fibrin clot properties in patients scheduled for transcatheter aortic valve implantation (TAVI)., Aims: We investigated whether TAVI patients display a more prothrombotic state, including suppressed fibrinolytic capacity compared to those undergoing surgery., Methods: We enrolled patients with advanced AS without significant atherosclerotic vascular disease scheduled for TAVI (n = 45) or surgical aortic valve replacement (SAVR, n = 59). Plasma fibrin clot features, including clot permeability (Ks) reflecting an average pore size, and lysis potential (Lys50), along with thrombin generation were determined off anticoagulation within 12 hours before the procedure., Results: TAVI patients compared to SAVR had prolonged Lys50 (median 420 [IQR, interquartile range, 337-480] seconds vs 379 [337-428] seconds; P = 0.045) and formed denser clots, reflected by lower Ks (3.66 [3.05-4.84] vs 4.36 [3.6-5.27] × 10-9 cm2; P = 0.02), but after adjustment for age the latter difference was no longer significant. Apart from age, concomitant diabetes mellitus, or chronic kidney disease, prolonged Lys50 was an independent predictor of indication for TAVI in AS patients on multivariate regression analysis. There was a delayed start of thrombin generation in TAVI patients (lag time, 4.5 [3.8-6.3] minutes vs 4.2 [3.3-4.7] minutes; P = 0.035), without other differences in thrombin generation parameters., Conclusions: This study is the first to show that patients scheduled for TAVI are characterized by prothrombotic fibrin clot properties including denser fibrin meshwork and more resistant to lysis compared with those undergoing SAVR, which might explain in part increased thromboembolic risk following TAVI.
- Published
- 2021
- Full Text
- View/download PDF
16. Increased levels of histidine-rich glycoprotein are associated with the development of post-thrombotic syndrome.
- Author
-
Siudut J, Natorska J, Son M, Plens K, and Undas A
- Subjects
- Adult, Aged, Biomarkers blood, Female, Humans, Male, Middle Aged, Postthrombotic Syndrome pathology, Postthrombotic Syndrome blood, Proteins analysis
- Abstract
Denser fibrin networks which are relatively resistant to lysis can predispose to post-thrombotic syndrome (PTS). Histidine-rich glycoprotein (HRG), a blood protein displaying antifibrinolytic properties, is present in fibrin clots. We investigated whether HRG may affect the risk of PTS in relation to alterations to fibrin characteristics. In venous thromboembolism (VTE) patients, we evaluated plasma HRG levels, plasma clot permeability, maximum absorbance, clot lysis time and maximum rate of increase in D-dimer levels released from clots after 3 months of the index event. We excluded patients with cancer and severe comorbidities. After 2 years of follow-up, 48 patients who developed PTS had 18.6% higher HRG at baseline. Baseline HRG positively correlated with clot lysis time, maximum absorbance, and thrombin-activatable fibrinolysis inhibitor (TAFI) activity but was inversely correlated with plasma clot permeability and maximum rate of increase in D-dimer levels released from clots. On multivariate regression model adjusted for age, fibrinogen and glucose, independent predictors of PTS were recurrent VTE, baseline HRG level, and TAFI activity. VTE recurred in 45 patients, including 30 patients with PTS, and this event showed no association with elevated HRG. Our findings suggest that increased HRG levels might contribute to the development of PTS, in part through prothrombotic fibrin clot properties.
- Published
- 2020
- Full Text
- View/download PDF
17. Impaired Fibrinolysis in Patients with Isolated Aortic Stenosis is Associated with Enhanced Oxidative Stress.
- Author
-
Siudut J, Natorska J, Wypasek E, Wiewiórka Ł, Ostrowska-Kaim E, Wiśniowska-Śmiałek S, Plens K, Legutko J, and Undas A
- Abstract
Aortic stenosis (AS) has been associated with impaired fibrinolysis and increased oxidative stress. This study aimed to investigate whether oxidative stress could alter fibrin clot properties in AS. We studied 173 non-diabetic patients, aged 51-79 years, with isolated AS. We measured plasma protein carbonylation (PC) and thiobarbituric acid reactive substances (TBARS), along with plasma clot permeability (K
s ), thrombin generation, and fibrinolytic efficiency, which were evaluated by two assays: clot lysis time (CLT) and lysis time (Lys50). Coagulation factors and fibrinolytic proteins were also determined. Plasma PC showed an association with AS severity, reflected by the aortic valve area and the mean and maximum aortic gradients. Plasma PC was positively correlated with CLT, Lys50, plasminogen activator inhibitor-1 (PAI-1), and tissue factor (TF) antigens. TBARS were positively correlated with maximum aortic gradient, Lys50, and TF antigen. Regression analysis showed that PC predicted prolonged CLT (>104 min; odds ratio (OR) 6.41, 95% confidence interval (CI) 2.58-17.83, p < 0.001) and Lys50 (>565 s; OR 5.83, 95% CI 2.23-15.21, p < 0.001). Multivariate regression analysis showed that mean aortic gradient, PC, α2-antiplasmin, PAI-1, and triglycerides were predictors of prolonged CLT, while PC, α2-antiplasmin, and fibrinogen were predictors of Lys50. Our findings suggest that elevated oxidative stress contributes to impaired fibrinolysis in AS and is associated with AS severity.- Published
- 2020
- Full Text
- View/download PDF
18. Sex-specific alteration to α2-antiplasmin incorporation in patients with type 2 diabetes.
- Author
-
Bryk AH, Siudut J, Broniatowska E, Bagoly Z, Baráth B, Katona É, and Undas A
- Subjects
- Female, Fibrin, Fibrin Clot Lysis Time, Fibrinolysis, Humans, Male, alpha-2-Antiplasmin, Antifibrinolytic Agents, Diabetes Mellitus, Type 2
- Abstract
Background: Type 2 diabetes mellitus (T2DM) is associated with hypofibrinolysis and increased factor XIII-mediated α2-antiplasmin incorporation into the fibrin clot. It is unclear whether there are sex-related differences in α2-antiplasmin incorporation in relation to impaired clot lysis in T2DM., Aim: We investigated α2-antiplasmin incorporation into fibrin clots as a determinant of clot lysability in patients of both sexes with T2DM., Methods: In a group of 113 T2DM patients, 54 (47.8%) of which were women, we investigated α2-antiplasmin incorporation using an in-house sandwich enzyme-linked immunoassay and plasma clot lysis by turbidimetry, along with fibrinogen and thrombin generation using calibrated automated thrombogram and factor XIII activity., Results: Female patients had 15.2% greater α2-antiplasmin incorporation into the fibrin clot (p = 0.008) and slightly higher plasma α2-antiplasmin concentration (p = 0.005) along with 8.4% longer time to 50% lysis (Lys50
MA , p = 0.012) compared with men. Female patients had enhanced thrombin generation represented by shorter lag phase (p = 0.042), shorter time to peak (p = 0.033), and higher endogenous thrombin potential (p = 0.003) compared with men, while factor XIII activity was comparable between sexes (p = 0.085). On multivariate regression, patient sex and glycated hemoglobin (HbA1c) level were the predictors of α2-antiplasmin incorporation in the entire patient group, while α2-antiplasmin incorporation was associated with Lys50MA , as were fibrinogen, male sex and body-mass index., Conclusions: This study suggests that a more compromised fibrinolysis in diabetic women when compared with men could be in part mediated by increased α2-antiplasmin incorporation into the fibrin., (Copyright © 2019 The Authors. Published by Elsevier Ltd.. All rights reserved.)- Published
- 2020
- Full Text
- View/download PDF
19. Prothrombotic clot properties can predict venous ulcers in patients following deep vein thrombosis: a cohort study.
- Author
-
Polak MW, Siudut J, Plens K, and Undas A
- Subjects
- Adult, Body Mass Index, Cohort Studies, Female, Fibrin metabolism, Fibrin Clot Lysis Time, Humans, Male, Middle Aged, Postthrombotic Syndrome etiology, Risk Factors, Varicose Ulcer etiology, alpha-2-Antiplasmin analysis, Varicose Ulcer diagnosis, Venous Thrombosis complications
- Abstract
Venous ulcers are the most severe manifestation of post-thrombotic syndrome (PTS). We have previously demonstrated that formation of compact fibrin clots resistant to lysis is observed in patients following deep-vein thrombosis (DVT) who developed PTS. The current study investigated whether unfavourable fibrin clot properties can predict post-thrombotic venous ulcers. In a cohort study on 186 consecutive patients following DVT, we determined plasma fibrin clot characteristics, including clot permeability and lysability, inflammatory markers, thrombin generation, fibrinolysis proteins at 3 months since the index event. Occurrence of PTS and venous ulcers was recorded during follow-up (median, 53; range 24 to 76 months). Fifty-seven DVT patients (30.6%) developed PTS, including 12 subjects (6.45%) with a venous ulcer (4 individuals with recurrent ulcers). Patients who developed ulcers compared with the remainder had at enrolment 13.0% lower clot permeability (K
s ), 17.4% longer clot lysis time (CLT), 13.1% longer lag phase of clot formation, and 5.0% higher maximum absorbance, with no difference in fibrinogen, C-reactive protein, and thrombin generation. The baseline prothrombotic fibrin clot phenotype (Ks ≤ 6.5 × 10-9 cm2 and CLT > 100 min) was associated with a higher risk of ulcers [hazard ratio (HR), 5.37; 95% confidence interval (CI), 1.3-21.5]. A multivariate model adjusted for age, sex, and fibrinogen showed that independent predictors of the ulcer occurrence were body mass index (HR 1.53; 95% CI 1.30-1.86), CLT (HR 1.43; 95% CI 1.04-2.05), and α2 -antiplasmin (HR 0.95; 95% CI 0.90-0.99). This study suggests that formation of denser fibrin clots with impaired fibrinolysis predisposes to post-thrombotic venous ulcers.- Published
- 2019
- Full Text
- View/download PDF
20. Polyhedrocytes in blood clots of type 2 diabetic patients with high cardiovascular risk: association with glycemia, oxidative stress and platelet activation.
- Author
-
Gajos G, Siniarski A, Natorska J, Ząbczyk M, Siudut J, Malinowski KP, Gołębiowska-Wiatrak R, Rostoff P, and Undas A
- Subjects
- Aged, Aged, 80 and over, Biomarkers blood, Case-Control Studies, Diabetes Mellitus, Type 2 complications, Diabetes Mellitus, Type 2 diagnosis, Erythrocytes ultrastructure, Female, Humans, Male, Middle Aged, Prognosis, Risk Assessment, Risk Factors, Thromboembolism diagnosis, Thromboembolism etiology, Blood Coagulation, Blood Glucose metabolism, Blood Platelets metabolism, Diabetes Mellitus, Type 2 blood, Erythrocytes metabolism, Oxidative Stress, Platelet Activation, Thromboembolism blood
- Abstract
Background: Little is known about factors that affect the composition of contracted blood clots in specific diseases. We investigated the content of polyhedral erythrocytes (polyhedrocytes) formed in blood clots and its determinants in type 2 diabetes (T2D) patients., Methods: In 97 patients with long-standing T2D [median HbA
1c , 6.4% (interquartile range 5.9-7.8)], we measured in vitro the composition of blood clots, including a clot area covered by polyhedrocytes using scanning electron microscopy and the erythrocyte compression index (ECI), defined as a ratio of the mean polyhedrocyte area to the mean native erythrocyte area. Moreover, plasma fibrin clot permeability (Ks ), clot lysis time (CLT), thrombin generation, oxidative stress [total protein carbonyl (total PC), total antioxidant capacity and thiobarbituric acid reactive substances (TBARS)], and platelet activation markers were determined. The impact of glucose concentration on polyhedrocytes formation was assessed in vitro., Results: Polyhedrocytes content in contracted clots was positively correlated with glucose (r = 0.24, p = 0.028), glycated hemoglobin (r = 0.40, p = 0.024), total cholesterol (r = 0.22, p = 0.044), TBARS (r = 0.60, p = 0.0027), P-selectin (r = 0.54, p = 0.0078) and platelet factor-4, PF4 (r = 0.59, p = 0.0032), but not with thrombin generation, platelet count, Ks or CLT. Patients who formed more polyhedrocytes (≥ 10th percentile) (n = 83, 85.6%) had higher glucose (+ 15.7%, p = 0.018), fibrinogen (+ 16.6%, p = 0.004), lower red blood cell distribution width (RDW, - 8.8%, p = 0.034), reduced plasma clot density (- 21.8% Ks , p = 0.011) and impaired fibrinolysis (+ 6.5% CLT, p = 0.037) when compared to patients with lesser amount of polyhedrocytes (< 10th percentile). ECI and the content of polyhedrocytes were strongly associated with total PC (r = 0.79, p = 0.036 and r = 0.67, p = 0.0004, respectively). In vitro an increase of glucose concentration by 10 mmol/L was associated with 94% higher polyhedrocytes content (p = 0.033) when compared to the baseline (7.1 mM). After adjustment for age, sex and fibrinogen, multiple regression analysis showed that RDW was the only independent predictor of polyhedrocytes content in T2D (OR = 0.61, 95% CI 0.39-0.92)., Conclusions: Poor glycemic control, together with enhanced platelet activation and oxidative stress, increase the content of polyhedrocytes in blood clots generated in T2D patients.- Published
- 2018
- Full Text
- View/download PDF
21. Impaired plasminogen binding in patients with venous thromboembolism: Association with protein carbonylation.
- Author
-
Siudut J, Natorska J, Zabczyk M, Zajac D, Seweryn K, Rąpała-Kozik M, and Undas A
- Subjects
- Adolescent, Adult, Humans, Middle Aged, Venous Thromboembolism pathology, Young Adult, Plasminogen metabolism, Protein Carbonylation genetics, Venous Thromboembolism blood
- Abstract
Introduction: Venous thromboembolism (VTE) is associated with hypofibrinolysis. Its mechanisms are poorly understood. We investigated plasminogen-fibrin interaction and its association with fibrinolytic capacity and protein oxidation/carbonylation in VTE patients., Materials and Methods: Plasma-purified plasminogen conversion to plasmin and surface plasmon resonance employed for plasminogen-fibrin interactions were individually evaluated in all healthy controls and non-anticoagulated patients following VTE, 10-23months since the event. We also assessed plasma fibrin clot permeability (K
s ), clot lysis time (LT), activators and inhibitors of fibrinolysis together with oxidation/carbonylation markers., Results: VTE patients had impaired plasminogen binding to fibrin (apparent Kd, +290%, p=0.002), reduced rate of plasmin generation (-4.7%, p=0.001), and longer LT (+18.6%, p<0.001) compared with controls. Fibrinogen and Ks were similar in both groups. Apparent Kd correlated with LT (r=0.43, p=0.037), tissue plasminogen activator-plasminogen activator inhibitor 1 (tPA-PAI-1) complexes (r=0.63, p=0.012), and active PAI-1 (r=0.49, p=0.03). Compared with controls, VTE patients had higher thiobarbituric acid reactive substances (TBARS), total protein carbonyl content (PC), and lower total antioxidant capacity (all p<0.001), that all were associated with LT (r=0.61, r=0.56, and r=-0.47, respectively, all p<0.05). Impaired plasminogen binding to fibrin reflected by apparent Kd positively correlated with TBARS (r=0.48, p=0.032) and PC (r=0.54, p=0.013) in the whole group., Conclusions: Plasminogen-fibrin interactions are altered in young and middle-aged VTE patients, without known thrombophilias, except increased factor VIII. The mechanisms underlying these phenomena remain to be established., (Copyright © 2018 Elsevier Ltd. All rights reserved.)- Published
- 2018
- Full Text
- View/download PDF
22. Optimization of quantitative proteomic analysis of clots generated from plasma of patients with venous thromboembolism.
- Author
-
Stachowicz A, Siudut J, Suski M, Olszanecki R, Korbut R, Undas A, and Wiśniewski JR
- Abstract
Background: It is well known that fibrin network binds a large variety of proteins, including inhibitors and activators of fibrinolysis, which may affect clot properties, such as stability and susceptibility to fibrinolysis. Specific plasma clot composition differs between individuals and may change in disease states. However, the plasma clot proteome has not yet been in-depth analyzed, mainly due to technical difficulty related to the presence of a highly abundant protein-fibrinogen and fibrin that forms a plasma clot., Methods: The aim of our study was to optimize quantitative proteomic analysis of fibrin clots prepared ex vivo from citrated plasma of the peripheral blood drawn from patients with prior venous thromboembolism (VTE). We used a multiple enzyme digestion filter aided sample preparation, a multienzyme digestion (MED) FASP method combined with LC-MS/MS analysis performed on a Proxeon Easy-nLC System coupled to the Q Exactive HF mass spectrometer. We also evaluated the impact of peptide fractionation with pipet-tip strong anion exchange (SAX) method on the obtained results., Results: Our proteomic approach revealed 476 proteins repeatedly identified in the plasma fibrin clots from patients with VTE including extracellular vesicle-derived proteins, lipoproteins, fibrinolysis inhibitors, and proteins involved in immune responses. The MED FASP method using three different enzymes: LysC, trypsin and chymotrypsin increased the number of identified peptides and proteins and their sequence coverage as compared to a single step digestion. Peptide fractionation with a pipet-tip strong anion exchange (SAX) protocol increased the depth of proteomic analyses, but also extended the time needed for sample analysis with LC-MS/MS., Conclusions: The MED FASP method combined with a label-free quantification is an excellent proteomic approach for the analysis of fibrin clots prepared ex vivo from citrated plasma of patients with prior VTE.
- Published
- 2017
- Full Text
- View/download PDF
23. Plasma fibrin clot properties in the G20210A prothrombin mutation carriers following venous thromboembolism: the effect of rivaroxaban.
- Author
-
Janion-Sadowska A, Natorska J, Siudut J, Ząbczyk M, Stanisz A, and Undas A
- Subjects
- Adult, Blood Coagulation Tests, Case-Control Studies, Factor Xa Inhibitors blood, Factor Xa Inhibitors pharmacokinetics, Female, Fibrin ultrastructure, Fibrinolysis drug effects, Fibrinolysis genetics, Genetic Predisposition to Disease, Humans, Male, Microscopy, Electron, Scanning, Middle Aged, Phenotype, Pulmonary Embolism blood, Pulmonary Embolism diagnosis, Rivaroxaban blood, Rivaroxaban pharmacokinetics, Treatment Outcome, Venous Thromboembolism blood, Venous Thromboembolism diagnosis, Venous Thrombosis blood, Venous Thrombosis diagnosis, Blood Coagulation drug effects, Blood Coagulation genetics, Factor Xa Inhibitors therapeutic use, Fibrin metabolism, Mutation, Prothrombin genetics, Pulmonary Embolism drug therapy, Pulmonary Embolism genetics, Rivaroxaban therapeutic use, Venous Thromboembolism drug therapy, Venous Thromboembolism genetics, Venous Thrombosis drug therapy, Venous Thrombosis genetics
- Abstract
We sought to investigate whether the G20210A prothrombin mutation modifies plasma fibrin clot properties in patients after venous thromboembolism (VTE) and how rivaroxaban treatment affects these alterations. We studied 34 prothrombin mutation heterozygous carriers and sex- and age-matched 34 non-carriers, all at least three months since the first VTE episode, before and during treatment with rivaroxaban. Clot permeability (K
s ) and clot lysis time (CLT) with or without elimination of thrombin activatable fibrinolysis inhibitor (TAFI) were assessed at baseline, 2-6 hours (h) after and 20-25 h after intake of rivaroxaban (20 mg/day). At baseline, the prothrombin mutation group formed denser clots (Ks -12 %, p=0.0006) and had impaired fibrinolysis (CLT +14 %, p=0.004, and CLT-TAFI +13 %, p=0.03) compared with the no mutation group and were similar to those observed in 15 healthy unrelated prothrombin mutation carriers. The G20210A prothrombin mutation was the independent predictor for Ks and CLT before rivaroxaban intake. At 2-6 h after rivaroxaban intake, clot properties improved in both G20210A carriers and non-carriers (Ks +38 %, and +37 %, CLT -25 % and -25 %, CLT-TAFI -20 % and -24 %, respectively, all p<0.001), but those parameters were worse in the prothrombin mutation group (Ks -12.8 %, CLT +17 %, CLT-TAFI +13 %, all p<0.001). Rivaroxaban concentration correlated with fibrin clot properties. After 20-25 h since rivaroxaban intake most clot properties returned to baseline. Rivaroxaban-related differences in clot structure were confirmed by scanning electron microscopy images. In conclusion, rivaroxaban treatment, though improves fibrin clot properties, cannot abolish more prothrombotic fibrin clot phenotype observed in prothrombin mutation carriers following VTE.- Published
- 2017
- Full Text
- View/download PDF
24. Fibrin clot characteristics in acute ischaemic stroke patients treated with thrombolysis: the impact on clinical outcome.
- Author
-
Bembenek JP, Niewada M, Siudut J, Plens K, Członkowska A, and Undas A
- Subjects
- Aged, Aged, 80 and over, Blood Coagulation drug effects, Female, Fibrin Clot Lysis Time, Fibrinolysis drug effects, Follow-Up Studies, Humans, Male, Tissue Plasminogen Activator therapeutic use, Treatment Outcome, Brain Ischemia blood, Brain Ischemia drug therapy, Fibrin metabolism, Stroke blood, Stroke drug therapy, Thrombolytic Therapy
- Abstract
Fibrin clot properties in acute ischaemic stroke (AIS) are unfavourably altered, including faster formation of denser and poorly lysable fibre networks. We investigated clot properties in AIS patients treated with recombinant tissue plasminogen activator (rtPA) and their impact on clinical outcome. In 74 consecutive AIS patients eligible for rtPA treatment, we assessed ex vivo plasma fibrin clot formation, permeability (K
s ), and rtPA-induced lysis, along with peak thrombin generation, fibrinolysis proteins and inhibitors at three time points - on admission, after 24 hours and 3 months since stroke. Clinical outcome was assessed using the NIHSS and mRS scores. Compared with the pretreatment values, fibrin networks assessed 24 hours since thrombolysis were formed more slowly (+20.5 % lag phase on turbidimetry), were less compact (+36.9 % Ks ), composed of thinner fibres (-10.6 % lower maximum absorbancy [ΔAb]), which were lysed more rapidly (-20.8 % clot lysis time [CLT] and +7.1 % the rate of rtPA-induced D-dimer release from clots [D-Drate ]). Thrombin generation and fibrinolysis proteins remained elevated. Lower ΔAb (<0.86 at 405 nm), shorter CLT (<105 min), and higher D-Drate (>0.072 mg/l/min) assessed at baseline predicted good outcome (mRS 0-2) at 3 months after adjustment for age and fibrinogen. Logistic regression adjusted for potential confounders showed that good outcome at 3 months was predicted by pretreatment D-Drate , while pretreatment CLT predicted excellent outcome (mRS of 0-1). In conclusion, formation of denser fibrin clots displaying impaired lysability and pattern of their changes induced by thrombolysis may affect clinical outcome in AIS patients.- Published
- 2017
- Full Text
- View/download PDF
25. Neutrophil extracellular traps formation in patients with eosinophilic granulomatosis with polyangiitis: association with eosinophilic inflammation.
- Author
-
Natorska J, Ząbczyk M, Siudut J, Krawiec P, Mastalerz L, and Undas A
- Subjects
- Adult, Antibodies, Antineutrophil Cytoplasmic blood, Biomarkers blood, Case-Control Studies, Cells, Cultured, Churg-Strauss Syndrome diagnosis, Churg-Strauss Syndrome immunology, Eosinophil Cationic Protein blood, Eosinophils immunology, Extracellular Traps immunology, Female, Fluorescent Antibody Technique, Granulomatosis with Polyangiitis diagnosis, Granulomatosis with Polyangiitis immunology, Humans, Male, Microscopy, Electron, Scanning, Middle Aged, Neutrophils immunology, Neutrophils ultrastructure, Churg-Strauss Syndrome blood, Eosinophils metabolism, Extracellular Traps metabolism, Granulomatosis with Polyangiitis blood, Neutrophil Activation, Neutrophils metabolism
- Abstract
Objectives: Eosinophilic granulomatosis with polyangiitis (EGPA) is associated with an inflammation and the presence of antineutrophil cytoplasmic antibodies (ANCA). Thus, we investigated the impact of ANCAs and eosinophilic inflammation on neutrophil activation and extracellular traps (NETs) formation., Methods: We recruited 29 patients in the remission of EGPA (17 ANCA-negative and 12 ANCA-positive, including 7 p-ANCA-positive and 5 c-ANCA-positive patients). Healthy donors' neutrophils were stimulated with EGPA patients' serum. NETs formation was assessed by immunofluorescence and scanning electron microscopy., Results: EGPA patients presented enhanced ability to generate NETs compared to healthy subjects (20.3±8.2% vs. 2.7±1.5%, p=0.0036). However, there were no differences in NETs formation between ANCA-positive and ANCA-negative patients (23±11.2% vs. 17±6.1%, p=0.15). There was also no correlation between NETs generation and the amount of circulating DNA in EGPA patients. Among ANCA-positive patients, p-ANCA-positives showed the highest percentage of NETs as compared to cANCA-positive and ANCA-negative patients (27.3±10.3% vs. 17.8±10.5% and vs. 17±6.1%, both p<0.01, respectively). Eosinophils number correlated with the percentage of NETs in the whole EGPA group (r=0.53, p=0.039), but we failed to observe the correlation with an eosinophil cationic protein (r=0.49, p=0.058)., Conclusions: EGPA patients' serum has the ability to induce NETosis with no regard to the ANCA status in contrast to other vasculitides, where p-ANCA were considered as the main factor. Interestingly, NETs formation in EGPA patients connected with the number of eosinophils might be of major relevance. Further studies are required to assess which eosinophil-derived factors might be responsible for the neutrophils activation in EGPA patients.
- Published
- 2017
26. Altered Fibrin Clot Properties in Patients With Cerebral Venous Sinus Thrombosis: Association With the Risk of Recurrence.
- Author
-
Siudut J, Świat M, and Undas A
- Subjects
- Adult, Female, Fibrin Clot Lysis Time, Follow-Up Studies, Humans, Male, Middle Aged, Recurrence, Risk, Fibrin physiology, Fibrinolysis physiology, Sinus Thrombosis, Intracranial blood
- Abstract
Background and Purpose: Venous thromboembolism and ischemic stroke are associated with unfavorable fibrin clot structure and function. We hypothesized that denser fibrin networks displaying impaired lysability characterize patients with cerebral venous sinus thrombosis (CVST)., Methods: We assessed plasma fibrin clot properties in 50 patients (aged 38.9±9.8 years, 36 women) after the first CVST unrelated to trauma or malignancy after anticoagulation withdrawal and 50 well-matched controls. Recurrences were recorded during follow-up (18-46; median, 36 months)., Results: Clot permeability was lower in patients with CVST than in controls (Ks, 6.43±0.97 versus 7.3±1.2 10(-9) cm(2); P<0.001) and was associated with prolonged clot lysis time (103.0±16.8 versus 92.4±16.2 minutes; P<0.001), lower maximum rate of D-dimer release from clots (0.068 [0.064-0.071] versus 0.072 [0.067-0.078] mg/L per minute; P<0.001) and higher maximum D-dimer levels in the lysis assay (4.39±0.56 versus 4.19±0.46 mg/L, respectively; P=0.03). Patients with CVST had a slightly shorter lag phase (P=0.02) and higher maximum absorbance of fibrin gels on turbidimetry (P<0.001) compared with controls. Deficiencies in natural anticoagulants or antiphospholipid syndrome, and factor V Leiden occurred more often in the patients (P<0.05). CVST recurred in 6 patients (12%) and was associated with 21% higher baseline fibrinogen (P=0.007), 20% lower Ks (P=0.04) and 17% greater D-Dmax (P=0.01). Multiple logistic regression showed that only elevated D-Dmax (>4.83 mg/L) predicted CVST recurrence (odds ratio, 5.1; 95% confidence interval, 1.63-16.19) after adjustment for fibrinogen., Conclusions: CVST is associated with the formation of more compact plasma fibrin clots and resistance to fibrinolysis, which may predispose to the recurrence., (© 2015 American Heart Association, Inc.)
- Published
- 2015
- Full Text
- View/download PDF
27. Shotgun analysis of plasma fibrin clot-bound proteins in patients with acute myocardial infarction.
- Author
-
Suski M, Siudut J, Ząbczyk M, Korbut R, Olszanecki R, and Undas A
- Subjects
- Acute Disease, Humans, Middle Aged, Myocardial Infarction, Fibrin metabolism, Proteomics methods
- Abstract
Introduction: The presence and amount of the proteins within a plasma clot may influence clot properties, like susceptibility to fibrinolysis, however, the clot proteome has not yet been extensively described. The aim of the study was to investigate the protein composition of clots of four patients with acute myocardial infarction (AMI) in two time points: in the acute ischemic phase and two months later during the standard therapy., Materials and Methods: Shotgun proteomic method (2DLC-MS/MS) was used to investigate time-dependent protein composition changes of clots prepared ex vivo from citrated plasma of the peripheral blood of patients with AMI., Results: Proteomic analysis revealed a total number of 62 proteins identified in all 8 samples grouping into several distinct functional clusters (e.g. cholesterol transporter activity, immunoglobulin binding and peptidase regulatory activity). The protein signatures of clots differed significantly depending on time after ACS, showing 30% greater variability in protein composition of the clots prepared in the plasma two months after the onset of AMI. Several proteins potentially involved in clot formation and resolution showed an interesting pattern of changes over time., Conclusion: We provided the first qualitative analysis of proteomes of fibrin clots generated ex vivo in plasma taken from patients with AMI showing differences between clots generated in the acute ischemic phase and those prepared two months later. It might be hypothesized that differences involving proteins of potential influence on within-clot fibrinolysis and clot stability may partially explain time-dependent changes in the clots structure and firmness in patients with AMI., (Copyright © 2015 Elsevier Ltd. All rights reserved.)
- Published
- 2015
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.